Roche’s Actemra Beats Methotrexate In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
Interleukin-6 inhibitor is first biologic to show superiority in reducing signs and symptoms.
You may also be interested in...
FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.
FDA Calls Roche’s Arthritis Drug Actemra Effective Ahead Of Panel Meeting
First-in-class interleukin-6 receptor inhibitor may sidestep safety concerns seen with anti-TNFs.
Roche’s Actemra Gets Advisory Committee Review
FDA’s Arthritis Drugs Advisory Committee evaluates the interleukin-6 receptor inhibitor for rheumatoid arthritis July 29.